

03 April 2025

Oncology Treatments

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Data only available for all stages

- Atezolizumab (Tecentriq) <5
- Durvalumab (Imfinzi) <5
- Nivolumab (Opdivo) <5
- Pembrolizumab (Keytruda) 15
- Chemotherapy 52
- Radiotherapy 15
- Chemotherapy AND Radiotherapy <5
- Osimertinib <5

Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) <5
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <5
- Lonsurf (Trifluridine - tipiracil) <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Any other systemic anti-cancer therapy
Carboplatin <5, CX <5, FLOT 39, Etoposide+Carboplatin <5, IMDG 7
- Palliative care only Not available
- Zolbetuximab (Vyloy) <5

Q3 How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) <5
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <5
- Lonsurf (Trifluridine - tipiracil) <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 7
- Zolbetuximab (Vyloy) (+ OMDG) <5
- Any other systemic anti-cancer therapy
OMDG <5, OX 19, OX+Trazimera 6, Pembrolizumab <5

03 April 2025

- **Palliative care only** not available

Q4 How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

- 89

Q5. How many patients has your Trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

Data only available for all stages - 44

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.